Condition

Genital Neoplasms, Male

ClinicalTrials.gov condition label

Clinical trials13

Recruiting1

Common interventions18

Lead sponsors shown13

Clinical trials

13 shown

18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate CancerNCT06706921 · 2024-12-15

EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCNCT05150236 · 2022-04-29

High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical ProstatectomyNCT04461509 · 2021-04-06

Trial of NanoPac Focal Therapy for Prostate CancerNCT04221828 · 2020-10-20

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)NCT04249947 · 2020-02-28

Health Gatherings - For Your Health After CancerNCT03344757 · 2017-10-05

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate CancerNCT02606123 · 2015-10-01

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion CohortsNCT02266745 · 2014-07-01

Protection of Rectum From High Radiation Doses Using a SpacerNCT01918605 · 2013-06-01

MRI for Assessment of Hypoxia-Induced Prostate Cancer AggressivenessNCT01464216 · 2011-10-01

ACTIVE_NOT_RECRUITING

A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate CancerNCT00672009 · 2008-04-01

Glivec in Prostate Cancer Patients With Rising PSA Following Radical ProstectomyNCT01316458 · 2003-06-01

Study of Abiraterone Acetate in Patients With Advanced Prostate CancerNCT01217697

APPROVED_FOR_MARKETING

Common interventions

177Lu-PSMA-617DRUG1 18F-Fluciclovine PET/CT ScanDRUG1 18F-PSMADRUG1 Abiraterone AcetateDRUG1 Cultural CBSMBEHAVIORAL1 Diluted spacerDEVICE1 EPI-506DRUG1 IpilimumabDRUG1 IxabepiloneDRUG1 NanoPac (sterile nanoparticulate paclitaxel) Powder for SuspensionDRUG1 NivolumabDRUG1 Non-diluted spacerDEVICE1 P-PSMA-101 CAR-T cellsBIOLOGICAL1 Prednisone\PrednisoloneDRUG1 PT-112 InjectionDRUG1 RimiducidDRUG1 Standard CBSMBEHAVIORAL1 STI571 (Glivec®)DRUG1

Leading sponsors

Alessandro D'Agnolo1 Australian and New Zealand Urogenital and Prostate Cancer Trials Group1 Cedars-Sinai Medical Center1 ESSA Pharmaceuticals1 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.1 NanOlogy, LLC1 Novartis Pharmaceuticals1 Oslo University Hospital1 Poseida Therapeutics, Inc.1 Promontory Therapeutics Inc.1 University of Miami1 University of Oulu1 VA Greater Los Angeles Healthcare System1

Trial status mix

TERMINATED6

COMPLETED2

UNKNOWN2

ACTIVE_NOT_RECRUITING1

APPROVED_FOR_MARKETING1

RECRUITING1

Phase mix

PHASE27

NA2

PHASE12

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.